• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Williams Donald Allen

    4/29/21 5:44:51 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNCA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Williams Donald Allen

    (Last) (First) (Middle)
    C/O PALISADE BIO, INC.
    5800 ARMADA DR., SUITE 210

    (Street)
    CARLSBAD CA 92008

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/27/2021
    3. Issuer Name and Ticker or Trading Symbol
    PALISADE BIO, INC. [ PALI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ JD Finley, Attorney-in-Fact for Don Williams 04/29/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SNCA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNCA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Williams Donald Allen

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    4/29/21 5:56:25 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Trenschel Robert J. was granted 304,479 units of Common Stock

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    4/29/21 5:55:15 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Neal James R

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    4/29/21 5:54:14 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNCA
    SEC Filings

    View All

    Seneca Biopharma, Inc. filed SEC Form 8-K: Other Events (Amendment)

    8-K/A - PALISADE BIO, INC. (0001357459) (Filer)

    4/28/21 4:05:12 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seneca Biopharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    4/28/21 8:00:44 AM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seneca Biopharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    4/27/21 5:24:48 PM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNCA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.

    GERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (NASDAQ:SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS").  The Merger is expected to close on or about April 27, 2021 and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28, 2021 under the ticker "PALI". Seneca and LBS will announce the final exchange ratio prior to the common stock commencing trading on or about Wednesday, April 28, 2021. About Leading BioSciences, Inc.LBS is developing novel therapeutics des

    4/26/21 7:00:00 AM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study

    CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. ("LBS" or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (NASDAQ:SNCA), subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the dat

    4/20/21 7:00:00 AM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021

    GERMANTOWN, Md., April 12, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on April 9, 2021. At the Special Meeting, Seneca asked stockholders to approve six proposals related to its proposed merger transaction with Leading BioSciences, Inc. ("LBS"), a biopharma company advancing therapies for acute and chronic gastrointestinal complications. All proposals, with the exception of proposal #1 for a reverse stock split (the "Reverse Split Proposal"), were approved by Seneca stockholders. In order to solicit additional votes for the Reverse Split Proposal, the Special Meeting w

    4/12/21 7:00:00 AM ET
    $SNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care